Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2020-09, Vol.27 (5), p.297-298 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 298 |
|---|---|
| container_issue | 5 |
| container_start_page | 297 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 27 |
| creator | Palanques-Pastor, Tomás López-Briz, Eduardo Poveda Andrés, José Luis |
| description | The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6. |
| doi_str_mv | 10.1136/ejhpharm-2020-002322 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7447248</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2436758709</sourcerecordid><originalsourceid>FETCH-LOGICAL-b517t-9f60735402e3c1d1f1e36fcc80a71b6789d7256ec919f9426a8f3a25ac6011bb3</originalsourceid><addsrcrecordid>eNqNkV1rFDEYhQdRbKn9ByIBb7yJzdckEy-EsvVjoVCw2tuQySbdrDPJmGQW_fdm2XZbvRCvkpf3OYfzcprmJUZvMab8zG7W01qnERJEEESIUEKeNMcEMQGl5Ozp4d_yo-Y0Z9-jltJOMiqfN0eUMCkpZseNX4ZtHLZ2tKGA6IAPxabBzt99ALxO4Pr8yzVcxBtI6uSsKT6GdyD7ocw__ah7oDPQoKxt0pOdizcgTjsG6FvtQy5gcXWzvIBYvmieOT1ke3r3njTfPn74uvgML68-LRfnl7BvsShQOo4EbRkilhq8wg5byp0xHdIC91x0ciVIy62RWDrJCNedo5q02nCEcd_Tk-b93nea-9GuTD0s6UFNqaZNv1TUXv25CX6tbuNWCcYEYV01eHNnkOKP2eaiRp-NHQYdbJyzIgwj2iJOUEVf_4Vu4pxCPa9SlIu2E0hWiu0pk2LOybpDGIzUrk51X6fa1an2dVbZq8eHHET35VXgbA_04-Z_LdGD4hD1n5LfVaa7FQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436758709</pqid></control><display><type>article</type><title>Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Palanques-Pastor, Tomás ; López-Briz, Eduardo ; Poveda Andrés, José Luis</creator><creatorcontrib>Palanques-Pastor, Tomás ; López-Briz, Eduardo ; Poveda Andrés, José Luis</creatorcontrib><description>The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-002322</identifier><identifier>PMID: 32499314</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Antibodies, Monoclonal - therapeutic use ; clinical pharmacy ; Coronavirus Infections - drug therapy ; Coronavirus Infections - metabolism ; Coronaviruses ; COVID-19 ; Cytochrome ; Cytokines ; Disease transmission ; Drug Delivery Systems ; Drug dosages ; hospital pharmacy education ; Humans ; immunology ; Immunotherapy ; Infections ; infectious diseases ; intensive & critical care ; Interleukin-6 - metabolism ; Monoclonal antibodies ; Pandemics ; Pneumonia ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - metabolism ; Severe acute respiratory syndrome coronavirus 2 ; Short Report ; Studies ; Viral infections</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-09, Vol.27 (5), p.297-298</ispartof><rights>European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage</rights><rights>European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b517t-9f60735402e3c1d1f1e36fcc80a71b6789d7256ec919f9426a8f3a25ac6011bb3</citedby><cites>FETCH-LOGICAL-b517t-9f60735402e3c1d1f1e36fcc80a71b6789d7256ec919f9426a8f3a25ac6011bb3</cites><orcidid>0000-0002-1632-9674</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447248/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447248/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32499314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palanques-Pastor, Tomás</creatorcontrib><creatorcontrib>López-Briz, Eduardo</creatorcontrib><creatorcontrib>Poveda Andrés, José Luis</creatorcontrib><title>Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>clinical pharmacy</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - metabolism</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytochrome</subject><subject>Cytokines</subject><subject>Disease transmission</subject><subject>Drug Delivery Systems</subject><subject>Drug dosages</subject><subject>hospital pharmacy education</subject><subject>Humans</subject><subject>immunology</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>infectious diseases</subject><subject>intensive & critical care</subject><subject>Interleukin-6 - metabolism</subject><subject>Monoclonal antibodies</subject><subject>Pandemics</subject><subject>Pneumonia</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - metabolism</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Report</subject><subject>Studies</subject><subject>Viral infections</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkV1rFDEYhQdRbKn9ByIBb7yJzdckEy-EsvVjoVCw2tuQySbdrDPJmGQW_fdm2XZbvRCvkpf3OYfzcprmJUZvMab8zG7W01qnERJEEESIUEKeNMcEMQGl5Ozp4d_yo-Y0Z9-jltJOMiqfN0eUMCkpZseNX4ZtHLZ2tKGA6IAPxabBzt99ALxO4Pr8yzVcxBtI6uSsKT6GdyD7ocw__ah7oDPQoKxt0pOdizcgTjsG6FvtQy5gcXWzvIBYvmieOT1ke3r3njTfPn74uvgML68-LRfnl7BvsShQOo4EbRkilhq8wg5byp0xHdIC91x0ciVIy62RWDrJCNedo5q02nCEcd_Tk-b93nea-9GuTD0s6UFNqaZNv1TUXv25CX6tbuNWCcYEYV01eHNnkOKP2eaiRp-NHQYdbJyzIgwj2iJOUEVf_4Vu4pxCPa9SlIu2E0hWiu0pk2LOybpDGIzUrk51X6fa1an2dVbZq8eHHET35VXgbA_04-Z_LdGD4hD1n5LfVaa7FQ</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Palanques-Pastor, Tomás</creator><creator>López-Briz, Eduardo</creator><creator>Poveda Andrés, José Luis</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1632-9674</orcidid></search><sort><creationdate>20200901</creationdate><title>Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19</title><author>Palanques-Pastor, Tomás ; López-Briz, Eduardo ; Poveda Andrés, José Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b517t-9f60735402e3c1d1f1e36fcc80a71b6789d7256ec919f9426a8f3a25ac6011bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>clinical pharmacy</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - metabolism</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytochrome</topic><topic>Cytokines</topic><topic>Disease transmission</topic><topic>Drug Delivery Systems</topic><topic>Drug dosages</topic><topic>hospital pharmacy education</topic><topic>Humans</topic><topic>immunology</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>infectious diseases</topic><topic>intensive & critical care</topic><topic>Interleukin-6 - metabolism</topic><topic>Monoclonal antibodies</topic><topic>Pandemics</topic><topic>Pneumonia</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - metabolism</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Report</topic><topic>Studies</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palanques-Pastor, Tomás</creatorcontrib><creatorcontrib>López-Briz, Eduardo</creatorcontrib><creatorcontrib>Poveda Andrés, José Luis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palanques-Pastor, Tomás</au><au>López-Briz, Eduardo</au><au>Poveda Andrés, José Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>27</volume><issue>5</issue><spage>297</spage><epage>298</epage><pages>297-298</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. A bibliographic search was performed in Pubmed on the immune response to the disease, and in ClinicalTrials.gov on clinical trials with interleukin 6 blockers. Interleukin 6 is involved in the cytokine cascade, which originates as a consequence of an excessive immune response secondary to viral infection, aggravating lung affectation. Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as a strategy for treating the disease. Siltuximab is a monoclonal antibody indicated in Castleman's disease that could be administered in a single dose of 11 mg/kg in severe forms of COVID-19 that have increased interleukin 6.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>32499314</pmid><doi>10.1136/ejhpharm-2020-002322</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-1632-9674</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2020-09, Vol.27 (5), p.297-298 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7447248 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antibodies, Monoclonal - therapeutic use clinical pharmacy Coronavirus Infections - drug therapy Coronavirus Infections - metabolism Coronaviruses COVID-19 Cytochrome Cytokines Disease transmission Drug Delivery Systems Drug dosages hospital pharmacy education Humans immunology Immunotherapy Infections infectious diseases intensive & critical care Interleukin-6 - metabolism Monoclonal antibodies Pandemics Pneumonia Pneumonia, Viral - drug therapy Pneumonia, Viral - metabolism Severe acute respiratory syndrome coronavirus 2 Short Report Studies Viral infections |
| title | Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T15%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Involvement%20of%20interleukin%206%20in%20SARS-CoV-2%20infection:%20siltuximab%20as%20a%20therapeutic%20option%20against%20COVID-19&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Palanques-Pastor,%20Tom%C3%A1s&rft.date=2020-09-01&rft.volume=27&rft.issue=5&rft.spage=297&rft.epage=298&rft.pages=297-298&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-002322&rft_dat=%3Cproquest_pubme%3E2436758709%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2436758709&rft_id=info:pmid/32499314&rfr_iscdi=true |